Your browser doesn't support javascript.
loading
Prediction of postpartum hemorrhage in pregnant women with immune thrombocytopenia: Development and validation of the MONITOR model in a nationwide multicenter study.
Huang, Qiu-Sha; Zhu, Xiao-Lu; Qu, Qing-Yuan; Liu, Xiao; Zhang, Gao-Chao; Su, Yan; Chen, Qi; Liu, Feng-Qi; Sun, Xue-Yan; Liang, Mei-Ying; Liu, Yi; Jiang, Ming; Liu, Hui; Feng, Ru; Yao, Hong-Xia; Zhang, Lei; Qian, Shen-Xian; Yang, Tong-Hua; Zhang, Jing-Yu; Shen, Xu-Liang; Yang, Lin-Hua; Hu, Jian-Da; Huang, Ren-Wei; Jiang, Zhong-Xing; Wang, Jing-Wen; Zhang, Hong-Yu; Xiao, Zhen; Zhan, Si-Yan; Liu, Hui-Xin; Chang, Ying-Jun; Jiang, Qian; Jiang, Hao; Lu, Jin; Xu, Lan-Ping; Zhang, Xiao-Hong; Yin, Cheng-Hong; Wang, Jian-Liu; Huang, Xiao-Jun; Zhang, Xiao-Hui.
Afiliación
  • Huang QS; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Zhu XL; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Qu QY; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Liu X; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Zhang GC; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Su Y; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Chen Q; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Liu FQ; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Sun XY; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Liang MY; Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China.
  • Liu Y; Department of Hematology, Navy General Hospital, Beijing, China.
  • Jiang M; Center of Hematologic Diseases, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  • Liu H; Department of Hematology, Beijing Hospital, Beijing, China.
  • Feng R; Department of Hematology, Beijing Hospital, Beijing, China.
  • Yao HX; Department of Hematology, People's Hospital of Hainan Province, Haikou, China.
  • Zhang L; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Qian SX; Department of Hematology, First People's Hospital of Hangzhou, Hangzhou, China.
  • Yang TH; Department of Hematology, First People's Hospital of Yunnan Province, Kunming, China.
  • Zhang JY; Department of Hematology, Hebei Institute of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
  • Shen XL; Department of Hematology, He Ping Central Hospital of the Changzhi Medical College, Changzhi, China.
  • Yang LH; Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China.
  • Hu JD; Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
  • Huang RW; Department of Hematology, Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
  • Jiang ZX; Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Wang JW; Department of Hematology, Beijing Tongren Hospital, Beijing, China.
  • Zhang HY; Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China.
  • Xiao Z; Department of Hematology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
  • Zhan SY; Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China.
  • Liu HX; Department of Clinical Epidemiology, Peking University People's Hospital, Beijing, China.
  • Chang YJ; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Jiang Q; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Jiang H; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Lu J; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Xu LP; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Zhang XH; Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China.
  • Yin CH; Department of Internal Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
  • Wang JL; Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China.
  • Huang XJ; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Zhang XH; Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Collaborative Innovation Center of Hematology; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Am J Hematol ; 96(5): 561-570, 2021 05 01.
Article en En | MEDLINE | ID: mdl-33606900
ABSTRACT
Globally, postpartum hemorrhage (PPH) is the leading cause of maternal death. Women with immune thrombocytopenia (ITP) are at increased risk of developing PPH. Early identification of PPH helps to prevent adverse outcomes, but is underused because clinicians do not have a tool to predict PPH for women with ITP. We therefore conducted a nationwide multicenter retrospective study to develop and validate a prediction model of PPH in patients with ITP. We included 432 pregnant women (677 pregnancies) with primary ITP from 18 academic tertiary centers in China from January 2008 to August 2018. A total of 157 (23.2%) pregnancies experienced PPH. The derivation cohort included 450 pregnancies. For the validation cohort, we included 117 pregnancies in the temporal validation cohort and 110 pregnancies in the geographical validation cohort. We assessed 25 clinical parameters as candidate predictors and used multivariable logistic regression to develop our prediction model. The final model included seven variables and was named MONITOR (maternal complication, WHO bleeding score, antepartum platelet transfusion, placental abnormalities, platelet count, previous uterine surgery, and primiparity). We established an easy-to-use risk heatmap and risk score of PPH based on the seven risk factors. We externally validated this model using both a temporal validation cohort and a geographical validation cohort. The MONITOR model had an AUC of 0.868 (95% CI 0.828-0.909) in internal validation, 0.869 (95% CI 0.802-0.937) in the temporal validation, and 0.811 (95% CI 0.713-0.908) in the geographical validation. Calibration plots demonstrated good agreement between MONITOR-predicted probability and actual observation in both internal validation and external validation. Therefore, we developed and validated a very accurate prediction model for PPH. We hope that the model will contribute to more precise clinical care, decreased adverse outcomes, and better health care resource allocation.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Complicaciones Hematológicas del Embarazo / Púrpura Trombocitopénica Idiopática / Hemorragia Posparto Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Newborn / Pregnancy País/Región como asunto: Asia Idioma: En Revista: Am J Hematol Año: 2021 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Complicaciones Hematológicas del Embarazo / Púrpura Trombocitopénica Idiopática / Hemorragia Posparto Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Newborn / Pregnancy País/Región como asunto: Asia Idioma: En Revista: Am J Hematol Año: 2021 Tipo del documento: Article País de afiliación: China